Insider Selling: Ocular Therapeutix (NASDAQ:OCUL) Insider Sells $231,673.50 in Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Namrata Saroj sold 35,370 shares of the firm’s stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $6.55, for a total value of $231,673.50. Following the completion of the transaction, the insider owned 220,522 shares in the company, valued at approximately $1,444,419.10. This trade represents a 13.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ocular Therapeutix Stock Performance

Shares of NASDAQ:OCUL traded up $0.26 during trading on Monday, hitting $6.85. The company’s stock had a trading volume of 3,554,946 shares, compared to its average volume of 3,877,324. Ocular Therapeutix, Inc. has a 12 month low of $6.00 and a 12 month high of $16.44. The firm has a market cap of $1.50 billion, a price-to-earnings ratio of -4.82 and a beta of 1.22. The company has a debt-to-equity ratio of 0.14, a current ratio of 13.10 and a quick ratio of 13.03. The company has a 50-day moving average of $8.40 and a 200-day moving average of $9.02.

Ocular Therapeutix (NASDAQ:OCUL) last issued its quarterly earnings results on Monday, November 9th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.06). The firm had revenue of $12.87 million for the quarter, compared to analysts’ expectations of $14.27 million. Ocular Therapeutix had a negative net margin of 579.10% and a negative return on equity of 59.89%. Ocular Therapeutix’s revenue for the quarter was down 11.5% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.38) EPS. On average, sell-side analysts expect that Ocular Therapeutix, Inc. will post -1.47 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently commented on OCUL shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Ocular Therapeutix in a report on Thursday, October 15th. Royal Bank Of Canada reiterated an “outperform” rating on shares of Ocular Therapeutix in a report on Tuesday, September 29th. Chardan Capital reiterated a “buy” rating and issued a $23.00 price target on shares of Ocular Therapeutix in a research note on Friday, October 2nd. Wall Street Zen raised shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Zacks Research raised shares of Ocular Therapeutix from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 12th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Ocular Therapeutix has a consensus rating of “Moderate Buy” and a consensus target price of $23.33.

More Ocular Therapeutix News

Here are the key news stories impacting Ocular Therapeutix this week:

• Neutral Sentiment: Investors are also watching for updates on the timing of a potential AXPAXLI filing; the earnings-preview coverage identified this as a key point of focus, but the provided reports do not specify a timing change. Ocular Therapeutix Earnings Preview: AXPAXLI Filing Timing in Focus
• Negative Sentiment: OCUL reported a quarterly loss of $0.42 per share, worse than analysts’ $0.36 expected loss and the $0.37 loss a year earlier. Revenue of $12.87 million also fell short of the $14.27 million consensus and declined 11.5% year over year. The earnings miss and weaker sales were cited as reasons for the share-price pressure. Ocular Therapeutix falls on third quarter earnings miss
• Negative Sentiment: Coverage also pointed to pipeline-related AXPAXLI costs alongside declining DEXTENZA sales, highlighting pressure from development spending and the commercial performance of an existing product. Ocular Therapeutix Q3 2026: AXPAXLI Pipeline Costs Bite as DEXTENZA Slides

Institutional Trading of Ocular Therapeutix

A number of hedge funds and other institutional investors have recently bought and sold shares of OCUL. Rockefeller Capital Management L.P. bought a new position in shares of Ocular Therapeutix in the fourth quarter worth about $31,000. Integrated Wealth Concepts LLC bought a new stake in Ocular Therapeutix during the 2nd quarter valued at about $51,000. Sterling Capital Management LLC lifted its holdings in Ocular Therapeutix by 401.7% during the 3rd quarter. Sterling Capital Management LLC now owns 6,612 shares of the biopharmaceutical company’s stock valued at $51,000 after buying an additional 5,294 shares in the last quarter. Root Financial Partners LLC purchased a new stake in Ocular Therapeutix in the 3rd quarter valued at about $66,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in Ocular Therapeutix in the 3rd quarter valued at about $86,000. Hedge funds and other institutional investors own 59.21% of the company’s stock.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company focused on developing and commercializing treatments for eye diseases and conditions. Based in Bedford, Massachusetts, the company uses its proprietary hydrogel-based technology to deliver medicines to the eye over time.

Its marketed product, DEXTENZA, is a corticosteroid insert placed in the tear duct by an eye-care professional to treat inflammation and pain following ophthalmic surgery. Ocular Therapeutix also develops investigational therapies for retinal diseases and other eye conditions, including treatments designed for sustained drug delivery.

The company was founded in 2006 and serves the U.S.